
Plexus (PLXS) Stock Forecast & Price Target
Plexus (PLXS) Analyst Ratings
Bulls say
Plexus Corp's revenue performance in the Healthcare/Life Sciences segment reflects a positive trajectory, with a year-over-year increase of 5% for the full year, culminating in $1.629 billion, and expectations of high-single- to low-double-digit growth driven by multiple program ramps in the upcoming quarters. The Aerospace and Defense segment is positioned for sequential growth in FQ1, underpinning the company's goal of 9-12% revenue growth company-wide, bolstered by increases in commercial air and defense-related programs. Overall, Plexus's strategic focus on integrated lifecycle solutions across demanding sectors is supported by strong customer demand recovery, which positions the company for sustainable earnings growth beyond revenue metrics.
Bears say
Plexus Corp's gross margin decreased to 9.9% from 10.1% in the prior quarter, indicating potential challenges in cost management and pricing power. Additionally, the Aerospace & Defense segment, contributing 16% of total revenues, experienced a 6% decline both quarter-over-quarter and year-over-year, reflecting ongoing issues in demand. Furthermore, the company anticipates a high-single-digit decrease in Industrial revenues in the next quarter due to seasonality and moderating demand, coupled with broader economic concerns such as tariff pressures and risks related to manufacturing disruptions.
This aggregate rating is based on analysts' research of Plexus and is not a guaranteed prediction by Public.com or investment advice.
Plexus (PLXS) Analyst Forecast & Price Prediction
Start investing in Plexus (PLXS)
Order type
Buy in
Order amount
Est. shares
0 shares